Viewing Study NCT06834360


Ignite Creation Date: 2025-12-25 @ 2:16 AM
Ignite Modification Date: 2025-12-26 @ 12:46 AM
Study NCT ID: NCT06834360
Status: RECRUITING
Last Update Posted: 2025-11-28
First Post: 2025-02-14
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Sponsor: Sanofi
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module